DEF: Plus Therapeutics Seeks Shareholder Approval for Reverse Stock Split and $50M Capital Raise Amid Nasdaq Compliance Challenge

Plus Therapeutics, a biotechnology company focused on CNS cancers, is seeking shareholder approval for a significant capital raise and a reverse stock split to address Nasdaq listing compliance while advancing its radiotherapeutic pipeline and CNSide diagnostic platform.

Summary

• Plus Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on August 7, 2025, to vote on several key proposals.
• Shareholders will vote on the election of six directors for a one-year term.
• A proposal seeks approval for the potential issuance and sale of up to $50,000,000 of common stock and up to $1,000,000 in commitment shares to Lincoln Park Capital Fund, LLC, to comply with Nasdaq Listing Rule 5635(d).
• The company is requesting discretionary authority for its board of directors to effect a reverse stock split at a ratio between 1-for-2 and 1-for-250 within 12 months, primarily to regain compliance with Nasdaq's minimum bid price requirement.
• A non-binding advisory vote on executive compensation will also be held.
• Shareholders will vote on approving the Fifth Amendment and Restatement of the 2020 Stock Incentive Plan, which would increase the shares available for issuance by 20,000,000.
• In mid-2024, Plus Therapeutics acquired CNSide, a cerebrospinal fluid assay platform for CNS cancer detection and management, which it believes addresses a $6 billion market opportunity.
• The company plans to reintroduce CNSide in Texas in the second half of 2025, with a subsequent rollout to all 50 states.
• Key milestones for CNSide include multiple scientific publications, inclusion in National Comprehensive Cancer Center Guidelines, positive FORSEE clinical trial results, establishment of a Houston testing laboratory, and hiring of an experienced diagnostics executive team.
• The lead investigational radiotherapeutic drug, REYOBIQ, is being evaluated for leptomeningeal metastases (LM), pediatric brain cancer (PBC), and recurrent glioblastoma (rGBM).
• The ReSPECT-LM safety trial was completed in early 2025, and a dose optimization trial is now enrolling patients for a future US registrational trial.
• The FDA cleared Plus Therapeutics to begin enrolling patients in a Phase 1/2a clinical trial for pediatric brain cancer, building on successful Phase 1 adult glioblastoma trial data published in Nature Communications in early 2025.
• The glioblastoma Phase 2 trial, ReSPECT-GBM, continues to enroll patients in 2025.
• Clinical trials continue to benefit from approximately $25,000,000 in aggregate grant support.
• The company reported a net loss of $(12,978) thousand in 2024, compared to $(13,316) thousand in 2023 and $(20,275) thousand in 2022.
• As of June 18, 2025, there were 60,490,101 shares of common stock outstanding.
• The company dismissed BDO USA, P.C. and engaged CBIZ CPAs P.C. as its new independent registered public accounting firm on July 16, 2025.

Sentiment

Score: 4

Explanation: The sentiment is mixed but leans negative due to significant financial challenges, including Nasdaq non-compliance requiring a reverse stock split and a substantial capital raise, alongside an identified material weakness in internal controls. While there is positive clinical and product development progress, the financial instability and potential dilution overshadow these achievements in the short term.

Positives

• Significant progress in advancing the radiotherapeutic pipeline, including REYOBIQ's development for three types of central nervous system cancers.
• Successful completion of the ReSPECT-LM safety trial and ongoing enrollment in a dose optimization trial for a US registrational trial.
• FDA clearance for a Phase 1/2a clinical trial for pediatric brain cancer, building on successful Phase 1 adult glioblastoma trial data showing substantial safety margins and efficacy signals, published in Nature Communications.
• Continued enrollment in the ReSPECT-GBM Phase 2 trial.
• Clinical trials benefit from approximately $25,000,000 in aggregate grant support, reducing direct company funding needs for these programs.
• Strategic acquisition of CNSide, a novel cerebrospinal fluid assay platform, which is expected to fill a $6,000,000,000 market opportunity in CNS cancer diagnostics.
• Achievement of key milestones for CNSide, including multiple scientific publications, inclusion in National Comprehensive Cancer Center Guidelines, and positive FORSEE clinical trial results.
• Successful establishment of a centralized testing laboratory in Houston and validation of key commercial elements like pricing and reimbursement for CNSide.
• Hiring of an experienced diagnostics executive team to lead the CNSide commercial subsidiary.
• The board recommends approval of the capital raise and stock incentive plan, indicating confidence in the company's future direction and need for funding to support growth initiatives.

Negatives

• Received a Nasdaq notice on May 16, 2025, indicating non-compliance with the minimum bid price requirement ($1.00 per share) due to the closing bid price falling below this threshold for 30 consecutive business days, posing a risk of delisting.
• The company's net loss increased from $(20,275) thousand in 2022 to $(13,316) thousand in 2023 and $(12,978) thousand in 2024, primarily due to increases in research and development expenses and costs associated with litigation settlement.
• The proposal for a reverse stock split (1-for-2 to 1-for-250) is necessary to regain Nasdaq compliance, which often signals underlying stock price weakness and can be viewed negatively by investors.
• A material weakness in the company's internal control over financial reporting was identified as of December 31, 2023, specifically related to the application of appropriate accounting principles to significant and unusual grant revenue transactions.
• The potential issuance of up to $50,000,000 in common stock and $1,000,000 in commitment shares to Lincoln Park Capital Fund, LLC, could result in significant dilution to existing shareholders.

Risks

• Failure to maintain Nasdaq listing due to non-compliance with the minimum bid price requirement, potentially leading to delisting.
• Inability to regain compliance with Nasdaq listing standards, which could impact the company's ability to raise capital and investor perception.
• Potential for significant dilution to existing stockholders from the issuance of up to $50,000,000 in common stock and $1,000,000 in commitment shares under the Lincoln Park Purchase Agreement.
• The market price of common stock may not remain at a level sufficient to meet Nasdaq requirements even after a reverse stock split.
• Trading volatility often associated with low-priced stocks, which may discourage institutional investors and lead to higher transaction costs for individual stockholders.
• The identified material weakness in internal control over financial reporting as of December 31, 2023, related to grant revenue transactions, could impact financial reporting accuracy and investor confidence.
• Forward-looking statements are subject to substantial risks and uncertainties, including changes in global, regional, or local political, economic, business, competitive, market, and regulatory factors, which could cause actual results to differ materially from expectations.

Future Outlook

The company anticipates continued clinical progress for its radiotherapeutic technology and expects to realize commercial value from its strategic acquisition of CNSide. The reintroduction of the CNSide product is planned for Texas in the second half of 2025, with a subsequent launch across all 50 states. Enrollment for the Phase 1/2a clinical trial for pediatric brain cancer is expected to commence soon, and the ReSPECT-GBM Phase 2 trial will continue enrollment in 2025. The company intends to monitor its stock price to regain Nasdaq compliance and may implement a reverse stock split if necessary.

Management Comments

• "In the last year, Plus Therapeutics made significant progress in advancing our radiotherapeutic pipeline."
• "We continue to believe that our CNSide platform uniquely fills a $6 billion market opportunity in the CNS cancer diagnostic space."
• "We anticipate continued clinical progress for our radiotherapeutic technology and realizing commercial value from our strategic acquisition of CNSide."
• "On behalf of our employees, management and directors, I would like to express our deep appreciation to our stockholders and partners for their help and support in 2024 and beyond."

Industry Context

Plus Therapeutics operates in the highly specialized and capital-intensive biotechnology sector, specifically focusing on central nervous system (CNS) cancers through both radiotherapeutic drug development (REYOBIQ) and diagnostic platforms (CNSide). The acquisition of CNSide aligns with a broader industry trend of integrating diagnostics with therapeutics to enable more precise and personalized cancer management. The reliance on grant funding for clinical trials is typical for early to mid-stage biotech companies. The challenge of maintaining Nasdaq listing due to low share price is a common hurdle for smaller, development-stage biotechs, reflecting the inherent risks and often long timelines associated with drug development and commercialization in this industry.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for direct industry benchmarking of financial or clinical performance. It mentions using 'Radford Global Life Sciences Survey' for executive compensation benchmarking, but not for business performance assessment.

Management Changes

Corporate Governance

Related Party Transactions

• In May 2024, certain directors and executive officers (Company Insiders) participated in the May 2024 PIPE Financing, purchasing Private Placement Shares and accompanying Series A and Series B Warrants. The aggregate purchase price for Company Insiders was $98,500.88, with individual participation including Marc H. Hedrick, M.D. ($25,000.20), Andrew Sims ($10,000.08), Richard J. Hawkins ($10,000.08), Howard Clowes ($20,000.16), Robert Lenk, Ph.D. ($8,500.16), and Greg Petersen ($25,000.20). The terms were believed to be comparable to those available from unaffiliated third parties.

Stakeholder Impact

• Shareholders face potential significant dilution from the proposed capital raise and reverse stock split, but these actions are intended to maintain Nasdaq listing and support long-term growth initiatives.
• Employees and management are directly impacted by the proposed amendment to the 2020 Stock Incentive Plan, which aims to provide additional equity incentives for recruitment, retention, and motivation.
• Patients and the medical community could benefit from the continued development of radiotherapeutic drugs for CNS cancers and the commercialization of the CNSide diagnostic platform, potentially offering new treatment and management options.
• Creditors may view the capital raise positively as it aims to support the company's capital requirements and path to FDA approval, potentially improving financial stability.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders virtually on August 7, 2025, to vote on director elections, capital raise approval, reverse stock split authorization, executive compensation, and the 2020 Stock Incentive Plan amendment.
• Commence enrollment soon for the Phase 1/2a clinical trial for children with brain cancer.
• Continue enrolling patients in the ReSPECT-GBM Phase 2 trial in 2025.
• Reintroduce the CNSide product in Texas in the second half of 2025, followed by an extension of the launch to all 50 states.
• The Board of Directors will determine the exact ratio and effective time for the reverse stock split within 12 months of stockholder approval, if approved.
• Monitor the closing bid price of common stock to regain compliance with Nasdaq's minimum bid price requirement by November 12, 2025.
• File a current report on Form 8-K with the SEC within four business days of the Annual Meeting to publish final voting results.

Key Dates

Recommendation

Keywords

Biotechnology, Radiotherapeutics, CNS Cancer, Glioblastoma, Leptomeningeal Metastases, Pediatric Brain Cancer, CNSide, Diagnostics, Oncology, SEC Filing, Proxy Statement, Clinical Trials, Nasdaq Listing, Reverse Stock Split, Capital Raise, Corporate Governance